What happened with CDNA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CareDx helps doctors monitor patients after kidney, heart and lung transplants. Doctors order its AlloSure tests, AlloMap Heart and HeartCare, and CareDx analyzes patient samples and returns results to the doctors. It then generally bills the patient’s insurer rather than the doctor. These testing services generate most of its revenue.
CareDx also sells laboratories products for matching donors with recipients and monitoring transplants, including AlloSeq kits. Transplant centers pay for its software and patient-management services, including Ottr software, while its specialized pharmacy helps patients manage complex medication regimens.
Medicare supplies a large share of testing revenue, so payment depends heavily on its coverage criteria and reimbursement rates, as well as other insurers’ policies. Performing a test does not guarantee payment. CareDx conducts all U.S. testing at one California laboratory with no backup facility; it must maintain CLIA certification and required state licenses to continue testing and billing Medicare.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CareDx’s results hinge on transplant-test adoption and reimbursement; watch Eurofins Transplant Genomics and Devyser Diagnostics too, which compete in post-transplant monitoring but are absent from this list.
Natera competes for the same kidney, heart and lung transplant patients as CareDx, selling molecular tests directly and through laboratory and distribution partners to monitor rejection. Its organ-health testing business—not its cancer or women’s health tests—is the part to watch for pressure on CareDx’s sales and pricing.
Insight Molecular Diagnostics challenges CareDx with tests that measure donor DNA fragments in blood to monitor transplant rejection, including kits being developed for hospitals and transplant laboratories to run locally. Watch its progress with local testing, where practitioners value turnaround time and laboratories value the economics of processing samples.
CareDx depends on Thermo Fisher for transplant-test instruments, reagents and consumables, while competing with its One Lambda business in tissue typing used to match donors and recipients, or HLA typing. Watch both supplies for CareDx’s testing and One Lambda’s position in the hospital and laboratory tissue-typing market.
CareDx depends on Illumina’s DNA-reading instruments and consumables for transplant testing, and licenses its transplant sequencing products and donor-recipient tissue-typing patents. Illumina’s supply and licensing news therefore matters both to CareDx’s testing operations and to the transplant laboratory products it commercializes worldwide.
CareDx relies on QIAGEN for a proprietary buffer reagent used in transplant tests, even as the two compete in tissue typing used to match donors and recipients, or HLA typing. For CareDx, watch the supply of that specific reagent and QIAGEN’s tissue-typing business rather than its broader sales of molecular-testing equipment and consumables.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher supplies instruments and reagents CareDx uses for transplant testing, and its report also offers a read on the tissue-typing market in which both companies operate.
Look for specific commentary on relevant laboratory supplies and transplant tissue typing. Strength and smooth supply in those areas would point to a steadier environment for CareDx's tests and typing products; constraints or weakness would raise risk. Thermo Fisher's overall results alone, however, cannot show whether CareDx has adequate supply.
CareDx, Inc. earningsThis company
CareDx earns most of its revenue from transplant testing, and this report will show whether test-volume growth is translating into revenue that holds up after payer adjustments.
Compare test volume with testing-services revenue, and watch for refund reserves and collection adjustments on earlier tests. If both volume and revenue rise together, more tests are translating into recognized revenue. If volume rises but revenue lags, or refund and collection adjustments grow, payer terms or actual collections are reducing what CareDx earns from each test.
Natera, Inc. earningsNTRA
Natera also sells monitoring tests to kidney, heart and lung transplant patients, so its report can show whether competition for the same patients and transplant centers is intensifying.
Focus on Natera's transplant organ-health testing, not its cancer or women's health businesses. Growth and signs of wider use would mean tougher competition for CareDx's testing demand and transplant-center customers; weakness could mean less pressure, but would not prove CareDx won those customers.
